Home > News > Kereos' Collaborators Present on Targeted Therapies
November 15th, 2005
Kereos' Collaborators Present on Targeted Therapies
Abstract:
Kereos, a biotechnology company developing targeted imaging agents and therapeutics to improve the detection and treatment of cancer and cardiovascular disease, announced today that the company's collaborators at Washington University School of Medicine will be presenting preclinical data on two therapeutic candidates at the American Heart Association (AHA) Scientific Sessions this week. These agents are the first cardiovascular-targeted therapeutics in Kereos' pipeline of ligand-targeted emulsions, and represent two of the first applications of nanotechnology to treating cardiovascular disease.
Source:
prnewswire
Bookmark:
Possible Futures
Space Solar Power: Key to a Livable Planet Earth June 10th, 2013
Global Nanotechnology Drug Delivery Market 2012-2016 June 10th, 2013
Nanorobot tetanus treatment animation June 9th, 2013
New horizons to drive the future of Medicine: European Technology Platform on Nanomedicine intends to lead the domain June 8th, 2013
Nanomedicine
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Announcements
Less is More: Novel Cellulose Structure Requires Fewer Enzymes to Process Biomass to Fuel June 19th, 2013
Sound waves precisely position nanowires June 19th, 2013
Scientists Use Nanotechnology to Increase Thermal Stability of Essential Oils June 19th, 2013
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013